Seres Therapeutics 以 $175m 的价格将 VOWST 出售给 Nestlé Health Science，消除了债务并推进了主导产品 SER-155。 Seres Therapeutics sells VOWST to Nestlé Health Science for $175m, eliminating debt and advancing lead product SER-155.
Seres Therapeutics 已完成以约 1.75 亿美元的价格将其 VOWST 业务出售给雀巢健康科学。 Seres Therapeutics has finalized the sale of its VOWST business to Nestlé Health Science for roughly $175 million. 这笔交易消除了塞雷斯的债务,并允许其主要产品SER-155的推进,该产品针对高危细菌感染的患者. This transaction eliminates Seres' debt and allows for the advancement of its lead product, SER-155, targeting patients at high risk of bacterial infections. 该公司计划在更多人口中勘探SER-155,并正在为慢性肝病患者开发SER-147。 The company plans to explore SER-155 in additional populations and is also developing SER-147 for chronic liver disease patients. 销售将塞雷斯的财政资源扩展到2025年底。 The sale extends Seres' financial resources into late 2025.